Drugs in Dev. Dermatology
Phase II
Canada 
Lead Product(s) : EB06
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Velan Capital
Deal Size : $15.0 million
Deal Type : Private Placement
Edesa Biotech Secures $15M Private Placement Priced At-Market Under Nasdaq Rules
Details : The net proceeds from the offering will be used to fund the continued advancement of EB06, a CXCL10 monoclonal antibody, into a Phase 2 clinical study for patients with nonsegmental vitiligo.
Product Name : EB06
Product Type : Antibody
Upfront Cash : Undisclosed
February 13, 2025
Lead Product(s) : EB06
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Velan Capital
Deal Size : $15.0 million
Deal Type : Private Placement
Lead Product(s) : Thykamine
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : TSX Venture Exchange
Deal Size : $5.0 million
Deal Type : Private Placement
Devonian Announces Private Placement of up to $5 Million
Details : The proceeds will fund the clinical study programs for PUR0110 (thykamine) in particular the phase 2/3 program in pediatric atopic dermatitis, the phase 2 programs in radiodermatitis associated with radiotherapy and in Hand and Foot Syndrome and associat...
Product Name : PUR0110
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
May 19, 2023
Lead Product(s) : Thykamine
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : TSX Venture Exchange
Deal Size : $5.0 million
Deal Type : Private Placement
Lead Product(s) : EB06
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study
Details : EB06 is a monoclonal antibody which targets autoreactive T cells that destroy the pigment-producing cells of the epidermis. It binds and inhibits CXCL10 as it is involved in initiation of the disease and the maintenance of vitiligo lesions.
Product Name : EB06
Product Type : Antibody
Upfront Cash : Inapplicable
January 02, 2023
Lead Product(s) : EB06
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thykamine
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Thykamine (PUR0110) is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune d...
Product Name : PUR0110
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
December 10, 2022
Lead Product(s) : Thykamine
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thykamine
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the study, a significantly greater proportion of adult patients treated with Thykamine™ (PUR0110) cream 0.10% achieved an IGA of clear/almost clear and at least a 2-grade improvement from baseline in IGA (30.8%) compared to placebo (6.7%; P =.014).
Product Name : PUR0110
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
June 10, 2022
Lead Product(s) : Thykamine
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thykamine
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The benefit of PUR0110 (Thykamine) cream 0.10% was supported by a statistically significant effect on the primary and secondary endpoints of Body Surface Area (BSA), pruritis, and Patient-Oriented Eczema Measure score (POEM).
Product Name : PUR0110
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : Thykamine
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EB01
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : JSS Medical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone
Details : EB01 contains a non-steroidal anti-inflammatory compound known as an sPLA2 inhibitor. Edesa reported that all 46 subjects in the first cohort have been randomized and dosed with either Edesa's EB01 topical treatment or a placebo cream.
Product Name : EB01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 03, 2021
Lead Product(s) : EB01
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : JSS Medical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EB01
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : JSS Medical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Edesa Biotech Reports Positive Interim Results in Dermatitis Trial
Details : EB01 is designed to inhibit the inflammatory process at its inception rather than after inflammation has occurred, the company believes that the drug could potentially exert a powerful anti-inflammatory effect without the safety concerns of steroids.
Product Name : EB01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 06, 2021
Lead Product(s) : EB01
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : JSS Medical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thykamine
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : PurGenesis Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : According to the results from the study, Thykamine at 0.1% showed significant improvement in skin clearance versus placebo at all measured timelines, thereby meeting the primary endpoint. It showed a fast onset of the therapeutic effect.
Product Name : PUR0110
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
February 18, 2021
Lead Product(s) : Thykamine
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : PurGenesis Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EB01
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : JSS Medical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Edesa Biotech Marks Enrollment Milestone in Dermatitis Study
Details : EB01, is an investigational medicine that contains a non-steroidal anti-inflammatory compound known as an sPLA2 inhibitor met primary efficacy endpoint, which is the mean percent change from baseline on the CDSI at day 29.
Product Name : EB01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 12, 2021
Lead Product(s) : EB01
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : JSS Medical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
